Design and synthetic considerations of matrix metalloproteinase inhibitors.
Experimental evidence confirms that the matrix metalloproteinases (MMPs) play a fundamental role in a wide variety of pathologic conditions that involve connective tissue destruction including osteoarthritis and rheumatoid arthritis, tumor metastasis and angiogenesis, corneal ulceration, multiple sclerosis, periodontal disease, and atherosclerosis. Modulation of MMP regulation is possible at several biochemical sites, but direct inhibition of enzyme action provides a particularly attractive target for therapeutic intervention. Hypotheses concerning inhibition of specific MMP(s) with respect to disease target and/or side-effect profile have emerged. Examples are presented of recent advances in medicinal chemistry approaches to the design of matrix metalloproteinase inhibitors (MMPIs), approaches that address structural requirements and that influence potency, selectivity, and bioavailability. Two important approaches to the design, synthesis, and biological evaluation of MMPIs are highlighted: (1) the invention of alternatives to hydroxamic acid zinc chelators and (2) the construction of nonpeptide scaffolds. One current example in each of these two approaches from our own work is described.
Wyeth-Ayerst Research, Pearl River, New York 10965, USA. skotnij@war.wyeth.com
J S
JS
Skotnicki
A
A
Zask
F C
FC
Nelson
J D
JD
Albright
J I
JI
Levin
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D003238:Connective Tissue / Q000201:enzymology / Q000473:pathology; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use; D005109:Extracellular Matrix / Q000201:enzymology; D006801:Humans; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D009362:Neoplasm Metastasis; D010003:Osteoarthritis / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D010510:Periodontal Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology
D004791:Enzyme Inhibitors; D008666:Metalloendopeptidases